CO2020007275A2 - Dosage guidelines for mobilization of hematopoietic stem and progenitor cells - Google Patents
Dosage guidelines for mobilization of hematopoietic stem and progenitor cellsInfo
- Publication number
- CO2020007275A2 CO2020007275A2 CONC2020/0007275A CO2020007275A CO2020007275A2 CO 2020007275 A2 CO2020007275 A2 CO 2020007275A2 CO 2020007275 A CO2020007275 A CO 2020007275A CO 2020007275 A2 CO2020007275 A2 CO 2020007275A2
- Authority
- CO
- Colombia
- Prior art keywords
- mobilization
- compositions
- donor
- progenitor cells
- hematopoietic stem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
Abstract
La invención proporciona composiciones y métodos útiles para movilizar poblaciones de células madre y progenitoras hematopoyéticas dentro de un donante, así como para determinar si las muestras de células movilizadas son adecuadas para su liberación para la expansión ex vivo y/o para el uso terapéutico. De acuerdo con las composiciones y métodos descritos en el presente documento, las células madre y progenitoras hematopoyéticas movilizadas pueden extraerse de un donante y administrarse a un paciente para el tratamiento de diversos trastornos de células madre, incluyendo enfermedades hematopoyéticas, trastornos metabólicos, cánceres y enfermedades autoinmunitarias, entre otras. En ciertas realizaciones, las composiciones y métodos descritos en el presente documento conducen a la movilización de una población de células CD34dim que tienen efectos inmunosupresores y que pueden reducir la incidencia de la enfermedad de injerto contra huésped. The invention provides compositions and methods useful for mobilizing hematopoietic progenitor and stem cell populations within a donor, as well as for determining whether mobilized cell samples are suitable for release for ex vivo expansion and / or therapeutic use. According to the compositions and methods described herein, mobilized hematopoietic progenitor and stem cells can be extracted from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and diseases autoimmune, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft versus host disease.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/834,017 US10058573B1 (en) | 2017-12-06 | 2017-12-06 | Dosing regimens for the mobilization of hematopoietic stem cells |
US201762596056P | 2017-12-07 | 2017-12-07 | |
US16/101,676 US20190167726A1 (en) | 2017-12-06 | 2018-08-13 | Dosing Regimens for the Mobilization of Hematopoietic Stem Cells |
US201862753656P | 2018-10-31 | 2018-10-31 | |
US201862773954P | 2018-11-30 | 2018-11-30 | |
PCT/US2018/064335 WO2019113375A2 (en) | 2017-12-06 | 2018-12-06 | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020007275A2 true CO2020007275A2 (en) | 2020-07-31 |
Family
ID=66749948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0007275A CO2020007275A2 (en) | 2017-12-06 | 2020-06-16 | Dosage guidelines for mobilization of hematopoietic stem and progenitor cells |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3720494A2 (en) |
JP (2) | JP2021505172A (en) |
KR (1) | KR20200096942A (en) |
CN (1) | CN111712262A (en) |
AU (1) | AU2018378804A1 (en) |
BR (1) | BR112020011186A2 (en) |
CA (1) | CA3083783A1 (en) |
CO (1) | CO2020007275A2 (en) |
IL (1) | IL275077A (en) |
MX (1) | MX2020005878A (en) |
SG (1) | SG11202004913TA (en) |
WO (1) | WO2019113375A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
US20220401481A1 (en) * | 2019-11-01 | 2022-12-22 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
AU2021263754A1 (en) * | 2020-04-27 | 2022-12-01 | Ensoma, Inc. | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
EP4308694A1 (en) * | 2021-03-16 | 2024-01-24 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5233044A (en) | 1989-06-08 | 1993-08-03 | Millipore Corporation | Active esters for solid phase peptide synthesis |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2227512T3 (en) | 1991-12-02 | 2005-04-01 | Medical Research Council | PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO. |
GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
US6447766B1 (en) | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
ES2210255T3 (en) | 1993-06-08 | 2004-07-01 | Smithkline Beecham Corporation | METHODS TO IMPROVE THE BIOLOGICAL ACTIVITY OF CHEMIOCINES. |
GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
CA2250784C (en) | 1997-02-11 | 2004-04-20 | Mallinckrodt Chemical, Inc. | Reactor and method for solid phase peptide synthesis |
CA2731416A1 (en) | 1998-03-30 | 1999-10-07 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
JP2003524620A (en) | 1999-03-24 | 2003-08-19 | アノーメッド インコーポレイティド | Chemokine receptor binding heterocyclic compounds |
EP1244648B1 (en) | 1999-12-17 | 2009-04-15 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds |
WO2001085196A2 (en) | 2000-05-09 | 2001-11-15 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
US20040131585A1 (en) | 2000-06-05 | 2004-07-08 | Silviu Itescu | Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
PT1411918E (en) * | 2001-07-31 | 2012-03-06 | Genzyme Global S A R L | Methods to mobilize progenitor/stem cells |
ATE468861T1 (en) | 2001-08-16 | 2010-06-15 | Univ Pennsylvania | SYNTHESIS AND USE OF REAGENTS FOR ENHANCED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES |
US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US20060035829A1 (en) | 2004-08-13 | 2006-02-16 | Anormed Inc. | Chemokine combinations to mobilize progenitor/stem cells |
NZ565337A (en) | 2005-06-24 | 2011-04-29 | Recombinetics Inc | Using cytosine deaminases to diminish retroelement transfer from pigs to humans |
US8021867B2 (en) | 2005-10-18 | 2011-09-20 | Duke University | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity |
US20090221683A1 (en) * | 2005-10-18 | 2009-09-03 | Caritas St.Elizabeth Medical Center Of Boston, Inc | Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis |
AU2007281090A1 (en) * | 2006-08-02 | 2008-02-07 | Genzyme Corporation | Combination therapy |
RU2009108289A (en) * | 2006-08-07 | 2010-09-20 | Джензим Корпорейшн (Us) | COMBINED THERAPY |
EP1995316A1 (en) | 2007-05-25 | 2008-11-26 | Qiagen GmbH | Method for gentle purification of cells, cell production and cell transfection |
EP2009095A1 (en) | 2007-06-28 | 2008-12-31 | Innovalor AG | Method of generating glucose-responsive cells |
AU2008318430A1 (en) | 2007-10-31 | 2009-05-07 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
PE20100362A1 (en) | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
EP2270025A1 (en) | 2009-06-29 | 2011-01-05 | Centre National pour la Recherche Scientifique (CNRS) | Solid phase peptide synthesis of peptide alcohols |
BR112012020257A8 (en) | 2010-02-11 | 2018-02-14 | Recombinetics Inc | methods and apparatus for producing transgenic artiodactyls |
MX363013B (en) | 2011-02-25 | 2019-03-04 | Recombinetics Inc | Genetically modified animals and methods for making the same. |
US9388212B2 (en) | 2013-02-21 | 2016-07-12 | Chemical & Biopharmaceutical Laboratories Of Patras S.A. | Solid phase peptide synthesis via side chain attachment |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
CA2908227A1 (en) * | 2013-02-28 | 2014-09-04 | President And Fellows Of Harvard College | Methods and compositions for mobilizing stem cells |
US9169287B2 (en) | 2013-03-15 | 2015-10-27 | Massachusetts Institute Of Technology | Solid phase peptide synthesis processes and associated systems |
JP2019507596A (en) * | 2016-02-26 | 2019-03-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Hematopoietic stem cells with high engraftment |
US10058573B1 (en) * | 2017-12-06 | 2018-08-28 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem cells |
-
2018
- 2018-12-06 CA CA3083783A patent/CA3083783A1/en active Pending
- 2018-12-06 WO PCT/US2018/064335 patent/WO2019113375A2/en unknown
- 2018-12-06 BR BR112020011186-4A patent/BR112020011186A2/en unknown
- 2018-12-06 EP EP18829615.6A patent/EP3720494A2/en active Pending
- 2018-12-06 CN CN201880088815.6A patent/CN111712262A/en active Pending
- 2018-12-06 SG SG11202004913TA patent/SG11202004913TA/en unknown
- 2018-12-06 MX MX2020005878A patent/MX2020005878A/en unknown
- 2018-12-06 JP JP2020531468A patent/JP2021505172A/en active Pending
- 2018-12-06 AU AU2018378804A patent/AU2018378804A1/en active Pending
- 2018-12-06 KR KR1020207019222A patent/KR20200096942A/en active Search and Examination
-
2020
- 2020-06-02 IL IL275077A patent/IL275077A/en unknown
- 2020-06-16 CO CONC2020/0007275A patent/CO2020007275A2/en unknown
-
2023
- 2023-11-02 JP JP2023188499A patent/JP2024023226A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019113375A3 (en) | 2019-07-18 |
WO2019113375A2 (en) | 2019-06-13 |
CN111712262A (en) | 2020-09-25 |
MX2020005878A (en) | 2020-10-07 |
JP2024023226A (en) | 2024-02-21 |
KR20200096942A (en) | 2020-08-14 |
JP2021505172A (en) | 2021-02-18 |
SG11202004913TA (en) | 2020-06-29 |
IL275077A (en) | 2020-07-30 |
EP3720494A2 (en) | 2020-10-14 |
CA3083783A1 (en) | 2019-06-13 |
AU2018378804A1 (en) | 2020-06-11 |
BR112020011186A2 (en) | 2020-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020007275A2 (en) | Dosage guidelines for mobilization of hematopoietic stem and progenitor cells | |
BR112018076306A2 (en) | cd117 + cell suppression compositions and methods | |
CL2019003390A1 (en) | Cytokine grafted antibody proteins and methods of use in cancer treatment | |
CL2018003699A1 (en) | Methods for selecting a t-cell line and donor thereof for adoptive cell therapy (divisional application 201701110) | |
EA202091333A1 (en) | METHODS FOR ACTIVATION, MODIFICATION AND EXPANSION OF T-CELLS FOR TREATMENT OF CANCER AND RELATED MALIGNANT DISEASES | |
NI201100083A (en) | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS. | |
CO2020004906A2 (en) | Compositions and methods for the elimination of cd117 + cells | |
SG10201808258SA (en) | Improved methods for manufacturing adoptive cell therapies | |
WO2019084057A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
CU20130019A7 (en) | RECOMBINANT HUMAN FOLICULATING HORMONE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS | |
UY38389A (en) | IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS | |
CL2020003319A1 (en) | Chimeric growth factor receptors | |
MX2020005849A (en) | Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof. | |
CO2021006259A2 (en) | Antibody and drug conjugates (caf) with fc silencing and their uses | |
MX2021000954A (en) | Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria. | |
CO2020006855A2 (en) | Compositions and methods for cd2 + cell depletion | |
MX2020004910A (en) | Compositions and methods for the depletion of cd5+ cells. | |
EA201690323A1 (en) | METHODS OF TREATING EAR DISEASES IN CHILDREN | |
ECSP20000655A (en) | IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF ALFA-ENaC AND METHODS OF USE | |
BR112018010066A8 (en) | 5-HYDROXYTRIPTAMINE 1B RECEPTOR STIMULATING AGENT TO ENHANCE GRAFT POTENTIAL IN VIVO | |
MX2020005235A (en) | Transformed human cell and use thereof. | |
AR109279A1 (en) | ANTI-PLAZOMYCIN ANTIBODIES AND METHODS OF USE OF THE SAME | |
BR112021010804A2 (en) | Methods for selective in vivo expansion of gamma delta t cell populations and compositions thereof | |
AR105142A1 (en) | TREATMENT METHODS OF MULTIFORM GLIOBLASTOMA WITH T-CELL THERAPY | |
BR112013033807A2 (en) | pyrroloquinolinyl-pyrrolidin-2,5-dione formulations and methods for their preparation |